COVID-19 vaccine uptake, effectiveness, and waning in 82,959 health care workers: A national prospective cohort study in Wales.
COVID-19 vaccine uptake, effectiveness, and waning in 82,959 health care workers: A national prospective cohort study in Wales.
复制标题
COVID-19-82,959名卫生保健工作者的疫苗摄取，有效性和减弱：威尔士的一项国家前瞻性队列研究。
DOI：
10.1016/j.vaccine.2021.11.061
复制
发表时间：
2022-02-16
期刊：
影响因子：
5.5
通讯作者：
Lyons RA
中科院分区：
文献类型：
--
作者：
Bedston S;Akbari A;Jarvis CI;Lowthian E;Torabi F;North L;Lyons J;Perry M;Griffiths LJ;Owen RK;Beggs J;Chuter A;Bradley DT;de Lusignan S;Fry R;Richard Hobbs FD;Hollinghurst J;Katikireddi SV;Murphy S;O'Reily D;Robertson C;Shi T;Tsang RSM;Sheikh A;Lyons RA
截至2021年9月30日，90%的疫苗接种率，但贫困地区的接种率较低。BNT 162 b2在第二次给药后2周的有效率为85%，在第22周的有效率为52%。第二次给药后BNT 162 b2的有效性相当。虽然人口估计数表明疫苗对SARS-CoV-2感染的有效性很高，但对处于SARS-CoV-2暴露风险较高的卫生保健工作者的保护了解较少。我们于2020年12月7日至2021年9月30日对威尔士（英国）的医护人员进行了一项全国性队列研究。我们检查了任何COVID-19疫苗的摄取，以及BNT 162 b2 mRNA（Pfizer-BioNTech）对聚合酶链反应（PCR）证实的SARS-CoV-2感染的有效性。我们在SAIL数据库中使用了链接和常规收集的全国范围的数据。威尔士82，959名卫生保健工作者的数据可用，暴露时间延长至第二次剂量后26周。总体疫苗接种率很高（90%），大多数卫生保健工作者接种了BNT 162 b2疫苗（79%）。疫苗接种因年龄、工作人员角色、社会经济地位而异; 50-59岁和60岁以上的人接种疫苗的可能性是16-29岁的人的1.6倍。与护理和助产士相比，医疗和牙科工作人员以及专职医疗人员接种疫苗的可能性分别为1.5倍和1.1倍。BNT 162 b2疫苗的有效性被认为是强有力的，并且在考虑的特征中是一致的;第一次接种后3 - 6周为52%，第二次接种后2周为86%，尽管第二次接种后22周下降至53%。在吸收率上有一些变化，与未接种疫苗的人相比，接种疫苗的人感染PCR证实的SARS-CoV-2的风险降低。第二剂比第一剂提供了更强的保护作用，但我们的研究与七周后的减弱一致。
90% vaccine uptake by 30 Sept 2021, but uptake in more deprived areas was lower. BNT162b2 was 85% effective after 2 weeks from second dose and 52% from 22 weeks. Equitable effectiveness of BNT162b2 after second dose. While population estimates suggest high vaccine effectiveness against SARS-CoV-2 infection, the protection for health care workers, who are at higher risk of SARS-CoV-2 exposure, is less understood. We conducted a national cohort study of health care workers in Wales (UK) from 7 December 2020 to 30 September 2021. We examined uptake of any COVID-19 vaccine, and the effectiveness of BNT162b2 mRNA (Pfizer-BioNTech) against polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection. We used linked and routinely collected national-scale data within the SAIL Databank. Data were available on 82,959 health care workers in Wales, with exposure extending to 26 weeks after second doses. Overall vaccine uptake was high (90%), with most health care workers receiving the BNT162b2 vaccine (79%). Vaccine uptake differed by age, staff role, socioeconomic status; those aged 50–59 and 60+ years old were 1.6 times more likely to get vaccinated than those aged 16–29. Medical and dental staff, and Allied Health Practitioners were 1.5 and 1.1 times more likely to get vaccinated, compared to nursing and midwifery staff. The effectiveness of the BNT162b2 vaccine was found to be strong and consistent across the characteristics considered; 52% three to six weeks after first dose, 86% from two weeks after second dose, though this declined to 53% from 22 weeks after the second dose. With some variation in rate of uptake, those who were vaccinated had a reduced risk of PCR-confirmed SARS-CoV-2 infection, compared to those unvaccinated. Second dose has provided stronger protection for longer than first dose but our study is consistent with waning from seven weeks onwards.
登录
查看更多内容
DOI：
10.1016/s0140-6736(20)32661-1
发表时间：
2021-01-09
期刊：
Lancet (London, England)
影响因子：
--
作者：
Voysey M;Clemens SAC;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Collins AM;Colin-Jones R;Cutland CL;Darton TC;Dheda K;Duncan CJA;Emary KRW;Ewer KJ;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Goodman AL;Green CM;Green CA;Heath PT;Hill C;Hill H;Hirsch I;Hodgson SHC;Izu A;Jackson S;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Lawrie AM;Lelliott A;Libri V;Lillie PJ;Mallory R;Mendes AVA;Milan EP;Minassian AM;McGregor A;Morrison H;Mujadidi YF;Nana A;O'Reilly PJ;Padayachee SD;Pittella A;Plested E;Pollock KM;Ramasamy MN;Rhead S;Schwarzbold AV;Singh N;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Tarrant R;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;Watson MEE;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
3.5
作者：
Lyons RA;Jones KH;John G;Brooks CJ;Verplancke JP;Ford DV;Brown G;Leake K
通讯作者：
Leake K
DOI：
10.1016/s0140-6736(21)00677-2
发表时间：
2021-05-01
期刊：
Lancet (London, England)
影响因子：
--
作者：
Vasileiou E;Simpson CR;Shi T;Kerr S;Agrawal U;Akbari A;Bedston S;Beggs J;Bradley D;Chuter A;de Lusignan S;Docherty AB;Ford D;Hobbs FR;Joy M;Katikireddi SV;Marple J;McCowan C;McGagh D;McMenamin J;Moore E;Murray JL;Pan J;Ritchie L;Shah SA;Stock S;Torabi F;Tsang RS;Wood R;Woolhouse M;Robertson C;Sheikh A
通讯作者：
Sheikh A
影响因子：
12.7
作者：
Light, DW
通讯作者：
Light, DW